Michael R. Apostol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael R. Apostol has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Andrew F. Leuchter
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, USA
2 shared publications- Nicole Petersen
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, USA
2 shared publications - Timothy Jordan
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, USA
2 shared publications - Aaron Slan
TMS Clinical and Research Service, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, USA
1 shared publication - Alexander S. Young
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, United States
1 shared publication - Amy A. Ernst
From the Department of Emergency Medicine, University of New Mexico, Albuquerque
1 shared publication
Latest Publications
- Open Access
- 19 August 2025
- Published by Springer Nature in Research Square
Efficacy of 5x5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression
Accelerated repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for Major Depressive Disorder (MDD), with an FDA-cleared protocol utilizing 10 sessions of prolonged intermittent Theta Burst Stimulation (piTBS) per day for five days. However, it remains unclear how many sessions and pulses are necessary to achieve benefit. We examined efficacy of five stimulation sessions per day for five days (“5x5”) of either piTBS or individualized, electroencephalogram-based “resonant frequency” (RF) stimulation. We compared MDD symptom improvement (PHQ-9) between two groups: 1) accelerated patients (N = 40) undergoing 5x5 treatment (patients received piTBS or RF rTMS) and 2) conventional patients (N = 135) receiving standard once daily rTMS. Both protocols ameliorated MDD symptoms and there were no statistically significant differences in depression symptom changes (p = .07) between the accelerated 5x5 protocol (mean PHQ-9: pre-rTMS = 17.68, post-rTMS = 10.98) and conventional once-daily treatment (mean PHQ-9: pre-rTMS = 17.83, post-rTMS = 8.97). There was no significant difference in improvement between the piTBS and RF 5x5 protocols (p = 0.9). A PHQ-9 median split of 5x5 patients revealed that the top half of patients showed robust depression improvement (69%) while the bottom half received no significant benefit (8%) by day 5. However, the bottom half showed significant improvement (36%) at two-to-four-week follow up (p = 0.001). These results suggest 5x5 accelerated rTMS treatment is as effective as once daily rTMS treatment and that the efficacy of accelerated treatment may not be accurately assessed until weeks after treatment completion.
- 19 August 2025
- Published by Springer Nature in Research Square
Open AccessEfficacy of 5x5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression
Accelerated repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for Major Depressive Disorder (MDD), with an FDA-cleared protocol utilizing 10 sessions of prolonged intermittent Theta Burst Stimulation (piTBS) per day for five days. However, it remains unclear how many sessions and pulses are necessary to achieve benefit. We examined efficacy of five stimulation sessions per day for five days (“5x5”) of either piTBS or individualized, electroencephalogram-based “resonant frequency” (RF) stimulation. We compared MDD symptom improvement (PHQ-9) between two groups: 1) accelerated patients (N = 40) undergoing 5x5 treatment (patients received piTBS or RF rTMS) and 2) conventional patients (N = 135) receiving standard once daily rTMS. Both protocols ameliorated MDD symptoms and there were no statistically significant differences in depression symptom changes (p = .07) between the accelerated 5x5 protocol (mean PHQ-9: pre-rTMS = 17.68, post-rTMS = 10.98) and conventional once-daily treatment (mean PHQ-9: pre-rTMS = 17.83, post-rTMS = 8.97). There was no significant difference in improvement between the piTBS and RF 5x5 protocols (p = 0.9). A PHQ-9 median split of 5x5 patients revealed that the top half of patients showed robust depression improvement (69%) while the bottom half received no significant benefit (8%) by day 5. However, the bottom half showed significant improvement (36%) at two-to-four-week follow up (p = 0.001). These results suggest 5x5 accelerated rTMS treatment is as effective as once daily rTMS treatment and that the efficacy of accelerated treatment may not be accurately assessed until weeks after treatment completion.
- Open Access
- 25 April 2025
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (9) , 1319-1326
Comparing neuromodulation targets to reduce cigarette craving and withdrawal: a randomized clinical trial
Cigarette smoking remains the leading preventable cause of death, emphasizing the need for new therapeutics, such as repetitive transcranial magnetic stimulation (TMS). We tested the hypothesis that TMS to three targets would reduce cigarette craving and withdrawal by modulating connectivity within and between three canonical networks in a randomized clinical trial (ClinicalTrials.gov: NCT03827265). Participants (N = 72; DSM-5 tobacco use disorder, ≥1 year of daily smoking) received one session of TMS to hubs of canonical resting-state networks: the dorsolateral prefrontal cortex (dlPFC), superior frontal gyrus (SFG), posterior parietal cortex (PPC), and area v5 (control). Self-reports (craving, withdrawal, and negative affect) and resting-state functional connectivity were measured before and after stimulation. SFG stimulation significantly reduced craving (95% CI, 0.0476–7.9559) and withdrawal (95% CI, 0.9225–8.1063) versus control, with larger effects in men (D = 0.59) than in women (D = 0.30). SFG stimulation did not change network connectivity, whereas dlPFC stimulation increased somatomotor, default mode, and dorsal attention network connectivity. No severe or unexpected treatment-related adverse events occurred. These findings suggest that SFG shows promise as a target for smoking-cessation treatment, especially for men. Further trials are warranted to confirm efficacy and develop imaging biomarkers for precision neuromodulation.
- 25 April 2025
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (9) , 1319-1326
Open AccessComparing neuromodulation targets to reduce cigarette craving and withdrawal: a randomized clinical trial
Cigarette smoking remains the leading preventable cause of death, emphasizing the need for new therapeutics, such as repetitive transcranial magnetic stimulation (TMS). We tested the hypothesis that TMS to three targets would reduce cigarette craving and withdrawal by modulating connectivity within and between three canonical networks in a randomized clinical trial (ClinicalTrials.gov: NCT03827265). Participants (N = 72; DSM-5 tobacco use disorder, ≥1 year of daily smoking) received one session of TMS to hubs of canonical resting-state networks: the dorsolateral prefrontal cortex (dlPFC), superior frontal gyrus (SFG), posterior parietal cortex (PPC), and area v5 (control). Self-reports (craving, withdrawal, and negative affect) and resting-state functional connectivity were measured before and after stimulation. SFG stimulation significantly reduced craving (95% CI, 0.0476–7.9559) and withdrawal (95% CI, 0.9225–8.1063) versus control, with larger effects in men (D = 0.59) than in women (D = 0.30). SFG stimulation did not change network connectivity, whereas dlPFC stimulation increased somatomotor, default mode, and dorsal attention network connectivity. No severe or unexpected treatment-related adverse events occurred. These findings suggest that SFG shows promise as a target for smoking-cessation treatment, especially for men. Further trials are warranted to confirm efficacy and develop imaging biomarkers for precision neuromodulation.
- 16 November 2023
- Published by Springer Nature in Nature Mental Health
- Vol. 1 (12) , 1001-1012
Effects of transcranial magnetic stimulation to the dorsolateral prefrontal cortex on craving and state anxiety in tobacco use disorder
- 16 November 2023
- Published by Springer Nature in Nature Mental Health
- Vol. 1 (12) , 1001-1012
Effects of transcranial magnetic stimulation to the dorsolateral prefrontal cortex on craving and state anxiety in tobacco use disorder
- Open Access
- 8 September 2023
- Published by Center for Open Science in PsyArXiv
Stimulating the posterior parietal cortex reduces risk-taking propensity in people with tobacco use disorder
The manuscript is a "Letter to the Editor/Short Communication" and has no
- 8 September 2023
- Published by Center for Open Science in PsyArXiv
Open AccessStimulating the posterior parietal cortex reduces risk-taking propensity in people with tobacco use disorder
The manuscript is a "Letter to the Editor/Short Communication" and has no
- Open Access
- 3 February 2023
- Published by Center for Open Science in PsyArXiv
Effects of Repetitive Transcranial Magnetic Stimulation to the Dorsolateral Prefrontal Cortex on Withdrawal and State Anxiety in People Who Smoke Cigarettes
Abstinence from cigarettes is associated with withdrawal and anxiety symptoms, which are barriers to smoking cessation. Repetitive Transcranial Magnetic Stimulation (rTMS) reduces both withdrawal and anxiety symptoms; however, the extent to which withdrawal reductions depend on anxiety reductions isn’t known, which this study was designed to address. The two predictions were that 1) there would be a positive relationship between withdrawal symptoms and state anxiety (anxiety symptoms in the present moment) and 2) rTMS-related reductions in state anxiety would mediate reductions in withdrawal. Participants (N = 44) were adults ages 18 - 45 who reported daily use of 5+ cigarettes for 1+ years. Participants received single-session rTMS (10 Hz at 100% of motor threshold; 5s on; 10s off; 3000 pulses total) to the left dorsolateral prefrontal cortex (dlPFC; experimental site) and the visual cortex (v5; control site) in a randomized, crossover, single-blind, within-subjects design. They completed the Shiffman-Jarvik Withdrawal Scale (SJWS) and the State-Trait Anxiety Inventory (STAI) before and after each rTMS treatment. There were significant positive correlations between withdrawal and state anxiety before and after rTMS, p < .001. A mixed-effects linear model indicated that rTMS to dlPFC led to a significant reduction in SJWS craving subscale scores, p < .05. However, a mediation analysis suggested that state anxiety did not mediate the reduction in SJWS scores, p > .05. Withdrawal and state anxiety were positively related before and after rTMS, and rTMS to dlPFC reduced cigarette craving. Reductions in cigarette craving by rTMS were not mediated by effects of rTMS on feelings of anxiety. With the goal of understanding how rTMS influences the cognitive and affective markers of smoking, this study was a step towards elucidating the psychological mechanisms of rTMS on cigarette withdrawal and craving.
- 3 February 2023
- Published by Center for Open Science in PsyArXiv
Open AccessEffects of Repetitive Transcranial Magnetic Stimulation to the Dorsolateral Prefrontal Cortex on Withdrawal and State Anxiety in People Who Smoke Cigarettes
Abstinence from cigarettes is associated with withdrawal and anxiety symptoms, which are barriers to smoking cessation. Repetitive Transcranial Magnetic Stimulation (rTMS) reduces both withdrawal and anxiety symptoms; however, the extent to which withdrawal reductions depend on anxiety reductions isn’t known, which this study was designed to address. The two predictions were that 1) there would be a positive relationship between withdrawal symptoms and state anxiety (anxiety symptoms in the present moment) and 2) rTMS-related reductions in state anxiety would mediate reductions in withdrawal. Participants (N = 44) were adults ages 18 - 45 who reported daily use of 5+ cigarettes for 1+ years. Participants received single-session rTMS (10 Hz at 100% of motor threshold; 5s on; 10s off; 3000 pulses total) to the left dorsolateral prefrontal cortex (dlPFC; experimental site) and the visual cortex (v5; control site) in a randomized, crossover, single-blind, within-subjects design. They completed the Shiffman-Jarvik Withdrawal Scale (SJWS) and the State-Trait Anxiety Inventory (STAI) before and after each rTMS treatment. There were significant positive correlations between withdrawal and state anxiety before and after rTMS, p < .001. A mixed-effects linear model indicated that rTMS to dlPFC led to a significant reduction in SJWS craving subscale scores, p < .05. However, a mediation analysis suggested that state anxiety did not mediate the reduction in SJWS scores, p > .05. Withdrawal and state anxiety were positively related before and after rTMS, and rTMS to dlPFC reduced cigarette craving. Reductions in cigarette craving by rTMS were not mediated by effects of rTMS on feelings of anxiety. With the goal of understanding how rTMS influences the cognitive and affective markers of smoking, this study was a step towards elucidating the psychological mechanisms of rTMS on cigarette withdrawal and craving.
- Open Access
- 1 January 2023
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 8 (1) , 21-31
Sleep Problems in Preschoolers With Autism Spectrum Disorder Are Associated With Sensory Sensitivities and Thalamocortical Overconnectivity
- 1 January 2023
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 8 (1) , 21-31
Open AccessSleep Problems in Preschoolers With Autism Spectrum Disorder Are Associated With Sensory Sensitivities and Thalamocortical Overconnectivity
- 1 January 2022
- Published by Psi Chi, the International Honor Society in Psychology in Psi Chi Journal of Psychological Research
- Vol. 27 (1) , 33-45
Kill One to Save Five? How Time Pressure, Religiosity, and Framing Effects Impact Utilitarian Judgments
- 1 January 2022
- Published by Psi Chi, the International Honor Society in Psychology in Psi Chi Journal of Psychological Research
- Vol. 27 (1) , 33-45
Kill One to Save Five? How Time Pressure, Religiosity, and Framing Effects Impact Utilitarian Judgments
- 1 November 2021
- Published by Elsevier in Psychology of Sport and Exercise
- Vol. 57
Do not drop your gloves: “Winning” a fight in the National Hockey League does not improve chances to win the game
- 1 November 2021
- Published by Elsevier in Psychology of Sport and Exercise
- Vol. 57
Do not drop your gloves: “Winning” a fight in the National Hockey League does not improve chances to win the game
- 1 June 2019
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 37 (6) , 1114-1117
Thyroid stimulating hormone testing in ED evaluation of patients with atrial fibrillation and various psychiatric diagnoses
- 1 June 2019
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 37 (6) , 1114-1117
Thyroid stimulating hormone testing in ED evaluation of patients with atrial fibrillation and various psychiatric diagnoses